Device Week, Jan. 31, 2019 – Livongo's Acquisition Of myStrength; FDA Evaluates Peripheral Paclitaxel Devices Study
Executive Summary
In this edition of Device Week, Medtech Insight's Catherine Longworth chats with Marion Webb about Livongo's acquisition of behavioral health company myStrength and with Reed Miller about the controversy surrounding the meta-analysis finding of a higher mortality risk with paclitaxel-eluting peripheral devices.
Listen to the podcast via the player below:
Medtech Insight articles addressing topics discussed in this episode: